Heterologous prime-boost vaccination targeting MAGE-type antigens promotes tumor T-cell infiltration and improves checkpoint blockade therapy

BACKGROUND: The clinical benefit of immune checkpoint blockade (ICB) therapy is often limited by the lack of pre-existing CD8(+) T cells infiltrating the tumor. In principle, CD8(+) T-cell infiltration could be promoted by therapeutic vaccination. However, this remains challenging given the paucity...

Descripción completa

Detalles Bibliográficos
Autores principales: McAuliffe, James, Chan, Hok Fung, Noblecourt, Laurine, Ramirez-Valdez, Ramiro Andrei, Pereira-Almeida, Vinnycius, Zhou, Yaxuan, Pollock, Emily, Cappuccini, Federica, Redchenko, Irina, Hill, Adrian VS, Leung, Carol Sze Ki, Van den Eynde, Benoit J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Basic Tumor Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8420668/
https://www.ncbi.nlm.nih.gov/pubmed/34479921
http://dx.doi.org/10.1136/jitc-2021-003218

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8420668/
https://www.ncbi.nlm.nih.gov/pubmed/34479921
http://dx.doi.org/10.1136/jitc-2021-003218

Ejemplares similares